
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Autoimmune pancreatitis laboratory findings
Introduction
Overview
Overview
Laboratory findings consistent with the diagnosis of autoimmune pancreatitis may include increased serum IgG4 levels and hypergammaglobulinemia (>2 times the upper limit of normal in most patients), antilactoferrin antibody, anticarbonic anhydrase II antibody, other autoantibodies (ANA), rheumatoid factor (RF), IgG4-positive plasma cells, elevated serum alkaline phosphatase levels (ALP), elevated serum aminotransferases, ESR, and CA19-9.
Laboratory Findings
Laboratory Findings
Laboratory findings consistent with the diagnosis of autoimmune pancreatitis include:[1][2][3][4][5]
- Increased serum IgG4 levels and hypergammaglobulinemia (>2 times the upper limit of normal in most patients). Using a cutoff of 135Β mg/dL, serum IgG4 has following sensitivity and specificity:
- Sensitivity 95%
- Specificity 97%
- Antilactoferrin antibody
- Anticarbonic anhydrase II antibody
- Anti-plasminogen-binding protein (PBP) peptide antibodies[6]
- Rheumatoid factor (RF)
- IgG4-positive plasma cells
- Elevated serum alkaline phosphatase levels (ALP)
- Elevated serum aminotransferases
- Elevated ESR
- Elevated CA19-9
Fecal tests:
(a) Sudan staining of feces:
- A non-specific, qualitative test that is no longer used for the diagnosis of steatorrhea.
(b) 72-hour quantitative fecal fat (Gold standard):
- A quantitaive test that determines fecal fat excretion for over 24hrs.
- Fecal fat excretion of >7g/day is diagnostic of malabsorption.
- Patients with steatorrhea usually have an excretion of >10g of fat per day.
(c) Faecal elastase measurement (Test of choice):
- The most sensitive and specific test for pancreatic exocrine dysfunction.
- It can be done with a single random stool sample.
- The results are independent of pancreatic enzyme replacement therapy.
- A value of less than 200 ug/g indicates pancreatic insufficiency.[7][8][9][10]
Pancreatic function tests:
(a) Direct/ Invasive tests:
- Direct tests are used to assess pancreatic insufficiency in the early course of disease when patient has clinical symptoms but no radiology findings.
- Direct tests involve pancreatic stimulation via meal or hormonal secretagogues and assessment of pancreatic secretions in the duodenal fluid.
- Direct tests along with radiographic findings (pancreatic calcifications) are stll considered to be the gold standard for the diagnosis of chronic pancreatitis.[11][12][13][14]
- The limitation of direct tests is that they are costly and cumbersome.[11][12][13][14]
- Direct tests include:
- Secretin stimulation test
- Pancreozymin-secretin test
Secretin stimulation test is considered the gold standard functional test for diagnosis of chronic pancreatitis.
The observation that bi-carbonate production is impaired early in chronic pancreatitis has led to the rationale of use of this test in early stages of disease:
(b) Indirect/ Non-invasive tests:
Indirect tests are used to assess the complications of chronic pancreatitis.
- Indirect tests include:
- Faecal chymotrypsin, PABA, pancreolauryl
- Faecal elastase test
Indirect tests are not sensitive to assess pancreatic insufficiency in the early course of disease.[14][16]
References
References
- β Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, Okamoto A, Egawa N, Nakajima H (2003). “A new clinicopathological entity of IgG4-related autoimmune disease”. J. Gastroenterol. 38 (10): 982β4. doi:10.1007/s00535-003-1175-y. PMIDΒ 14614606.
- β Shinji A, Sano K, Hamano H, Unno H, Fukushima M, Nakamura N, Akamatsu T, Kawa S, Kiyosawa K (2004). “Autoimmune pancreatitis is closely associated with gastric ulcer presenting with abundant IgG4-bearing plasma cell infiltration”. Gastrointest. Endosc. 59 (4): 506β11. PMIDΒ 15044886.
- β Takeda S, Haratake J, Kasai T, Takaeda C, Takazakura E (2004). “IgG4-associated idiopathic tubulointerstitial nephritis complicating autoimmune pancreatitis”. Nephrol. Dial. Transplant. 19 (2): 474β6. PMIDΒ 14736977.
- β Saeki T, Saito A, Hiura T, Yamazaki H, Emura I, Ueno M, Miyamura S, Gejyo F (2006). “Lymphoplasmacytic infiltration of multiple organs with immunoreactivity for IgG4: IgG4-related systemic disease”. Intern. Med. 45 (3): 163β7. PMIDΒ 16508232.
- β Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K (2007). “Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis”. Hepatology. 46 (2): 463β71. doi:10.1002/hep.21700. PMIDΒ 17634963.
- β Frulloni L, Lunardi C, Simone R, Dolcino M, Scattolini C, Falconi M, Benini L, Vantini I, Corrocher R, Puccetti A (2009). “Identification of a novel antibody associated with autoimmune pancreatitis”. N. Engl. J. Med. 361 (22): 2135β42. doi:10.1056/NEJMoa0903068. PMIDΒ 19940298.
- β Freedman SD. “Clinical manifestations and diagnosis of chronic pancreatitis in adults”. UpToDate.
- β Keim V, Teich N, Moessner J (2003). “Clinical value of a new fecal elastase test for detection of chronic pancreatitis”. Clin. Lab. 49 (5β6): 209β15. PMIDΒ 15285176.
- β Walkowiak J, Herzig KH, Strzykala K, Przyslawski J, Krawczynski M (2002). “Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis”. Pediatrics. 110 (1 Pt 1): e7. PMIDΒ 12093988.
- β Borowitz D, Baker SS, Duffy L, Baker RD, Fitzpatrick L, Gyamfi J, Jarembek K (2004). “Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis”. J. Pediatr. 145 (3): 322β6. doi:10.1016/j.jpeds.2004.04.049. PMIDΒ 15343184.
- β 11.0 11.1 Boeck WG, Adler G, Gress TM (2001). “Pancreatic function tests: when to choose, what to use”. Curr Gastroenterol Rep. 3 (2): 95β100. PMIDΒ 11276375.
- β 12.0 12.1 Chowdhury RS, Forsmark CE (2003). “Review article: Pancreatic function testing”. Aliment. Pharmacol. Ther. 17 (6): 733β50. PMIDΒ 12641496.
- β 13.0 13.1 Siegmund E, LΓΆhr JM, Schuff-Werner P (2004). “[The diagnostic validity of non-invasive pancreatic function tests–a meta-analysis]”. Z Gastroenterol (in German). 42 (10): 1117β28. doi:10.1055/s-2004-813604. PMIDΒ 15508057.
- β 14.0 14.1 14.2 Ammann RW (2006). “Diagnosis and management of chronic pancreatitis: current knowledge”. Swiss Med Wkly. 136 (11β12): 166β74. doi:2006/11/smw-11182 Check
|doi=value (help). PMIDΒ 16633964. - β 15.0 15.1 Ketwaroo G, Brown A, Young B, Kheraj R, Sawhney M, Mortele KJ, Najarian R, Tewani S, Dasilva D, Freedman S, Sheth S (2013). “Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis”. Am. J. Gastroenterol. 108 (8): 1360β6. doi:10.1038/ajg.2013.148. PMCΒ 5388854. PMIDΒ 23711627.
- β Etemad B, Whitcomb DC (2001). “Chronic pancreatitis: diagnosis, classification, and new genetic developments”. Gastroenterology. 120 (3): 682β707. PMIDΒ 11179244.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2]
